We recently described a homozygous frameshift mutation in the human leptin (ob) gene associated with undetectable serum leptin and extreme obesity in two individuals (1). This represented the first identified genetic cause of morbid obesity in humans. Preliminary data suggested a defect in the secretion of this truncated (⌬133) mutant leptin. In the present investigation, we have examined the mechanisms underlying the defective secretion of the ⌬133 leptin in transient transfection studies in Chinese hamster ovary and monkey kidney epithelium cells. Consistent with our previous observations, only immunoreactive wild-type (wt) leptin was secreted. In pulse chase experiments, intracellular wt leptin levels decreased, concomitant with secretion into the medium. In contrast, though immunoreactive ⌬133 leptin disappeared from cell lysates with kinetics similar to those of wt leptin (half-life, 45 min), it was not detected in the medium. Inhibition of the proteasome, using the inhibitor clastolac-
tacystin ␤-lactone, led to a significant increase in the intracellular levels of ⌬133 leptin, indicating a role for the proteasome in the degradation pathway. Although intracellular immunoprecipitated wt and ⌬133 leptin levels were comparable, analysis of total cell lysates revealed a 7-fold increase in total intracellular ⌬133 leptin, compared with wt leptin. Size-exclusion membrane filtration demonstrated that intracellular ⌬133 leptin accumulated in an aggregated form, presumably as a result of misfolding in the endoplasmic reticulum. Consistent with this, an endoplasmic reticulum-like localization for ⌬133 leptin was detected by immunofluorescence microscopy. In conclusion, the ⌬133 mutant leptin is not secreted but accumulates intracellularly, as a consequence of misfolding/aggregation, and is subsequently degraded by the proteasome. These studies further define the genotype/phenotype correlation in this paradigmatic case of human leptin deficiency. (Endocrinology 140: 1718 -1723, 1999) L EPTIN IS A secreted peptide hormone of 16 kDa, which is encoded by the leptin (ob) gene on human chromosome 7q3l.3 (2, 3) . It is produced primarily by adipocytes, and extensive investigations in rodents have shown that it plays a key role in the regulation of food intake, weight balance, and energy expenditure (4 -7) .
Previously, we reported a homozygous mutation in the leptin gene in 2 extremely obese children with undetectable serum leptin (1) . The deletion of a single guanine nucleotide in codon 133 results in a frameshift mutation that leads to the introduction of 14 aberrant amino acids, followed by a premature stop codon. Preliminary data suggested a defect in the secretion of this truncated (⌬133) mutant leptin (1) . More recently, a homozygous missense mutation (R105W) in the human leptin (ob) gene was also found to associate with undetectable serum leptin, extreme obesity, and impaired secretion in transfected cells (8) .
Wild-type (wt) leptin contains an intrachain disulphide bond (9) that seems necessary for its biological activity (10) . The ⌬133 leptin protein lacks this disulphide bond, suggesting that, even if it were secreted, the protein would be inactive. In contrast, the intrachain disulphide bond may be intact in the R105W leptin; thus, it is less clear whether the R105W leptin protein would exhibit biological activity if its secretion defect were overcome. Wt leptin does not seem to be stored in adipocytes or in other cultured cell lines, suggesting that its secretion is constitutive rather than regulated. As a result, leptin secretion is thought to be regulated only by changes in transcription and/or translation (11) (12) (13) .
We have investigated the intracellular fate of the first reported functionally significant mutant human leptin protein, ⌬133, and its effect on synthesis and secretion of wt leptin. We demonstrate, by transfection studies in Chinese hamster ovary (CHO) and monkey kidney epithelium (COS7) cells, that the nucleotide deletion at codon 133 disrupts the intracellular trafficking and secretion of the truncated leptin protein. The proteasome is the major cytosolic protease responsible for the degradation of misfolded proteins, which are usually secreted or expressed at the cell surface (see Ref. 17) . By use of the proteasome inhibitor, clastolactacystin ␤-lactone, we implicate the proteasome in the degradation pathway of the truncated leptin protein. Cotransfection studies indicated that mutant leptin did not interfere with the synthesis and secretion of wt leptin. We have also confirmed the secretion defect reported for the R105W leptin in a second cell type. Attempts to overcome the secretion defect of the mutant leptins were without effect.
Materials and Methods
Chemicals and reagents. All chemicals and reagents were purchased from Sigma Chemical Co. (Dorset, UK) unless otherwise stated. Affinitypurified polyclonal antileptin antibodies (rabbit) M221, PC-B, and PC-3, were raised against nonreduced (M221 and PC-B) or reduced (PC-3) recombinant human leptin, respectively, and were generously donated by Amgen, Inc. (Thousand Oaks, CA). The polyclonal antileptin antibody (rabbit) LepA1 was a kind gift from Mediagnost (Tü bingen, Germany).
Cell lines. CHO.K1 cells were grown in Nutrient F-12 HAM medium supplemented with 10% FBS, 10 5 U/liter penicillin, 0.1 g/liter streptomycin, and 2 mm l-glutamine. COS7 cells were cultured in DMEM (4.5 g/liter glucose) supplemented as above. Cells were grown at 37 C under an atmosphere of 95% air-5% CO 2 unless otherwise stated. Cells grown at 29 C were incubated in HEPES-buffered Basal Medium Eagle medium.
Construction of R105W mutant leptin. All routine DNA manipulations were performed using standard protocols (14) . The pRc.CMV expression vectors (Invitrogen, Leek, Netherlands), encoding full-length wt or ⌬133 human leptin, have been described previously (1) . The R105W mutant leptin complementary DNA was constructed using a QuikChange Site-Directed Mutagenesis Kit (Stratagene, Cambridge, UK), in accordance with the manufacturer's instructions, and confirmed by direct sequencing.
Transient transfection of cells. Transfections were performed on cells grown in 30-cm 2 wells using equal amounts of the pRc.CMV expression vector encoding full-length wt, or ⌬133, or R105W mutant human leptins and Lipofectamine (Gibco BRL, Paisley, UK), in accordance with the manufacturer's instructions. Experiments were performed approximately 24 h after transfection.
Immunoprecipitation and Western blotting. Immunoprecipitation and Western blotting were performed as described previously (15) . In brief, for determination of secreted leptin, cells were maintained in fresh medium for approximately 20 h before analysis. Cultured medium was collected on ice, and an equal volume of lysis buffer (2ϫ) was added before immunoprecipitation. For determination of intracellular leptin, cells were rinsed once in ice-cold PBS, lysed, harvested, and precleared by centrifugation. Leptin was immunoprecipitated from samples using antileptin antibody (diluted 1:100) and 50 l of a 5% slurry of protein A-agarose. Immunoprecipitates, or total cell lysates, were electrophoresed on 15% SDS-polyacrylamide gels (SDS-PAGE) and were transferred by electroblotting to Immobilon-P polyvinylidene fluoride membranes (Millipore Corp., Bedford, MA). Blots were probed with antileptin antibody (diluted 1:5000), followed by [ 125 I]-labeled goat antirabbit antibody (16) . Proteins were visualized using a Fujix BAS 2000 PhosphorImager, Tokyo, Japan.
Metabolic labeling studies. Transfected cells were preincubated in prewarmed methionine and cysteine-free DMEM for 1 h. Then, 100 Ci [ 35 S] EasyTag Express Methionine/Cysteine Protein Labeling Mix (DuPont NEN, Hertfordshire, UK) was added to each well, and cells were further incubated for 45 min. Cells were then washed once using complete HAMS F12 medium and incubated in the same. At the appropriate time points, media and cells were harvested, and leptin was immunoprecipitated as described above. Immunoprecipitates were electrophoresed on 15% SDS-PAG and analyzed using a Fujix Bas 2000 PhosphorImager. Immunofluorescence microscopy. CHO cells were transfected using Tfx10, according to the manufacturer's instructions (Promega Corp., Southampton, UK). The proteasome was inhibited by lactacystin, as described above. Cells were fixed with 4% paraformaldehyde, permeabilized with methanol, blocked with 0.2% BSA, incubated first with the antileptin antibody, PCB (1:100), and then with goat antirabbit Texas Red-linked Ig (1:100, Jackson ImmunoResearch, Baltimore). Immunofluorescence microscopy was performed using a Bio-Rad MRC 1000 apparatus (Bio-Rad Laboratories Inc., Hertfordshire, UK).
Size-exclusion membrane filtration columns. Cell lysates from transfected CHO cells were run over Microcon-100 microconcentrators (Amicon, Beverly, MA), according to the manufacturer's instructions. Proteins collected within eluates and retentates were precipitated using trichloroacetic acid and analyzed by Western blotting, as described.
Results
After transfection of CHO and COS7 cells with expression vectors encoding wt and/or ⌬133 human leptin, intracellular and secreted leptin levels were determined by immunoprecipitation and Western blotting ( Fig. 1 ). Though intracellular levels of immunoreactive wt (16 kDa) and ⌬133 (14 kDa) leptin were comparable, only immunoreactive wt leptin was detected in the cultured medium from transfected CHO and COS7 cells. When cells were cotransfected with both wt and ⌬133 leptin, again both wt and ⌬133 leptin were found in cell lysates, and only immunoreactive wt leptin was found in the medium (Fig. 1 ). Thus, ⌬133 leptin did not seem to be secreted from cells. Expression of ⌬133 leptin did not inhibit the secretion of wt leptin from the same cells, because wt leptin was secreted with similar efficiency in the absence or presence of mutant leptin (100% vs. 92 Ϯ 18%, respectively, leptin secreted per microgram of wt complementary DNA).
To further characterize the fate of the ⌬133 leptin, pulse chase studies were performed. Transfected CHO cells were metabolically labeled for 45 min and then chased for up to 6 h in complete medium. Leptin was then immunoprecipitated from cell lysates and medium, subjected to SDS-PAGE, and analyzed using a PhosphorImager. The levels of intracellular radiolabeled wt leptin decreased with a concomitant increase in secreted leptin (Fig. 2, a and b ). Although the time course of the disappearance of intracellular radiolabeled ⌬133 leptin was similar to that of wt leptin, with both exhibiting a half-life of approximately 45 min, no ⌬133 leptin was detected in the medium.
From the above results, it was apparent that, although we were unable to detect secretion of ⌬133 leptin, we were also unable to detect accumulation of ⌬133 leptin within the cells. There are several possible explanations for these observa- tions. The ⌬133 leptin may become misfolded or aggregated, such that it is no longer immunoreactive; or it may be recognized as being improperly folded, and so, targeted for rapid degradation. To elucidate the fate of the ⌬133 leptin, we first examined the levels of leptin in cell lysates without immunoprecipitation. In contrast to the comparable levels of intracellular wt and ⌬133 leptin seen after immunoprecipitation of samples, analysis of samples without immunoprecipitation revealed there to be approximately 7-fold more intracellular ⌬133 leptin, compared with wt leptin (Fig. 3A,  lanes a and d) . Indeed, the efficiency of immunoprecipitation of ⌬133 leptin was found to be markedly lower than that of wt leptin [10 -15%, compared with 80 -90%, respectively (Fig.  3A, lanes b and e; and Fig. 3B ). Consistent with the observation that ⌬133 leptin was immunoprecipitated less efficiently than wt leptin, significant amounts of ⌬133 leptin remained in the supernatants of immunoprecipitates; but this was not the case for wt leptin (Fig. 3A , lanes c and f; and Fig. 3B ). These findings were confirmed using three different polyclonal antileptin antibodies (data not shown) and suggest that the ⌬133 leptin exists in a conformation that differs markedly from wt leptin.
It has long been recognized that misfolded forms of proteins, normally destined for secretion or surface expression by eukaryotic cells, fail to escape from the endoplasmic reticulum. Recent work has made a strong case that much, if not all, endoplasmic reticulum-associated proteolysis occurs in the cytosol and is mediated by the major cytosolic pro-tease, the proteasome (17) . Having shown that ⌬133 leptin was not secreted, but accumulated within the cells, we examined whether the proteasome played a role in degradation of the mutant leptin. Transfected CHO cells were treated with the proteasome inhibitor, clastolactacystin ␤-lactone, at a final concentration of 10 m, such that greater than 95% of proteasome activity would be irreversibly inhibited (18, 19) . Incubation of cells, in the presence of the proteasome inhibitor for 2 h, had no clear effect (data not shown); however, treatment for 16 h resulted in an increase of approximately 8-fold in the amount of intracellular ⌬133 leptin (Fig. 4) . Intracellular wt leptin levels were also slightly increased after Intracellular leptin levels were approximately 7-fold greater for ⌬133 leptin than wt leptin (ranging from 5-to 9-fold). Values for wt and ⌬133 leptin in total cell lysates (TCL) were both given the arbitrary value of 100%. Immunoprecipitable (IP) and nonimmunoprecipitable (SN) values were calculated accordingly.
16 h of incubation with the proteasome inhibitor, but to a much lesser degree (ϳ2-fold) than that seen for mutant leptin (Fig. 4 ). We believe that this modest effect on wt leptin is attributable to the overexpression of such an exogenous protein in CHO cells.
Initial attempts to detect either wt or ⌬133 leptin in transfected cells by immunofluorescence microscopy were unsuccessful, although a cytoplasmic marker protein, which was cotransfected, was readily detected in approximately 10 -20% of cells (data not shown). We reasoned that inhibition of the proteasome, which results in an increase in intracellular levels of ⌬133 leptin, in particular, may favor visualization of intracellular leptin. Such proteasomal inhibition did not facilitate detection of wt leptin in transfected cells by immunofluorescence microscopy (data not shown). However, upon treatment of cells with the proteasome inhibitor, we were able to detect intracellular ⌬133 leptin in a staining pattern consistent with localization in the endoplasmic reticulum (Fig. 5 ).
To determine whether ⌬133 leptin accumulated as aggregates within cells, total cell lysates were applied to sizeexclusion membrane filtration columns with a theoretical cut-off of approximately 100 kDa, and the eluates and retentates were analyzed by immunoblotting ( Fig. 6 ). These columns allow greater than 95% of proteins of less than 25-kDa molecular mass to flow through in the eluate. As expected, wt leptin was detected in the eluate, but the ⌬133 leptin was found only in the retentate. The absence of ⌬133 leptin in the eluate was consistent with the ⌬133 leptin aggregating within the cell. Interactions with other proteins, such as chaperones, may also be expected to prevent flow through to the eluate and cannot be ruled out. That said, we were unable to detect increased association/retention of the chaperone Ig heavy-chain binding protein with ⌬133 leptin, compared with wt leptin, in the above studies (data not shown), even though this chaperone is reported to show increased interactions with misfolded proteins (20) .
⌬133 leptin was also not detected in cultured medium when analyzed by direct immunoblotting or after application to size-exclusion membrane filtration columns or TCA pre-cipitation (data not shown). This rules out the possibility that the ⌬133 leptin is secreted in a native form that is nonimmunoreactive, such as the misfolded/aggregated form, and is consistent with the ⌬133 leptin being defective in its secretion.
Defective secretion of the recently described R105W mutant leptin has been reported in transfected COS cells (8) . Consistent with this, we found that it also exhibited defective secretion in transfected CHO cells ( Fig. 7) , with R105W leptin being undetectable in cultured media, whereas wt leptin was readily detected (Fig. 7, a and b ). Analogous to the accumulation of intracellular ⌬133 leptin, described above, the R105W leptin accumulated intracellularly, compared with wt leptin (Fig. 7, a and b) . Treatment of cells with lowmolecular-weight compounds or incubation at reduced temperatures has been shown to alleviate folding defects of certain mutant proteins (21) . Similar attempts to relieve the block on R105W leptin secretion, by incubating cells expressing R105W leptin at 29 C or in the presence of 6% glycerol, failed to do so (Fig. 7, c and d) . Identical treatment of cells expressing the ⌬133 leptin also had no effect (data not shown).
Discussion
We have recently reported a mutation in the human leptin gene associated with extreme early onset obesity and hyperphagia in two first cousins (1) . Both affected subjects were homozygous for a frameshift mutation caused by deletion of a guanine nucleotide in codon 133. This mutation leads to the following abnormalities: loss of the normal 34 C-terminal amino acids, including the C-terminal cysteine known to be essential for intrachain disulphide bond formation and leptin's tertiary structure (9) ; replacement of these amino acids by 14 aberrant amino acids and a premature stop codon; and undetectable serum leptin levels in affected subjects despite their gross obesity (1) . Preliminary evidence was presented that ⌬133 leptin failed to be secreted from transfected CHO cells (1) .
Because these probands represent the first naturally occurring mutations in human leptin to be described and, in addition, one of the very small number of human subjects with naturally occurring mutations in a secreted peptide hormone, we wished to establish the molecular mechanism underlying defective secretion of the ⌬133 leptin. In the studies reported above, we have: confirmed that the ⌬133 leptin fails to be secreted into the culture medium in two independent cell types; determined that the ⌬133 leptin accumulates within cells; shown that the ⌬133 leptin is less immunoreactive than wt leptin, presumably as a result of conformational changes; shown that the ⌬133 leptin forms macromolecular aggregates within the cell; demonstrated, by using specific inhibitors of proteasome action, that ⌬133 leptin is targeted to and degraded by the proteasome; and finally, in cotransfection experiments, that the ⌬133 leptin does not interfere with secretion of wt leptin.
Thus, this genetic form of obesity in the two related probands may be added to a growing list of human diseases that are associated with mutations that interfere with protein folding and trafficking. For example, the most common mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) leads to retention of the encoded protein within the endoplasmic reticulum and degradation by the ubiquitin-proteasome pathway (17, 22, 23) . Other examples of mutations affecting protein trafficking include mutations in the insulin receptor (24, 25) and thyroglobulin (26) .
The data we present is consistent with the ⌬133 leptin aggregating in the endoplasmic reticulum. Accordingly, we were able to demonstrate an endoplasmic reticulum-like staining pattern for ⌬133 leptin, by immunofluorescence microscopy, after treatment of the cells with the proteasome inhibitor. However, we were unable to detect wt leptin in transfected cells, with or without inhibition of the proteasome, despite using several polyclonal antibodies against leptin. This is in contrast to the findings of Barr et al. (27) , who were able to detect intracellular wt leptin in the endoplasmic reticulum of cells from rat epididymal fat pads, by similar methods. The reason(s) for our inability to detect wt leptin using these methodologies is unclear. However, explanations, including low efficiency of translation in nonadipose cell types and/or rapid transit through the cell, may be invoked.
Recently, further genetic evidence has come to light confirming the importance of leptin in the control of human body weight. Clement et al. (28) have reported a Kabilian family where severely obese individuals are homozygous for a nonsense mutation in the leptin receptor. A Turkish family has also been reported, in which homozygosity for a missense mutation in the leptin gene (R105W) is associated with extreme early onset obesity and low plasma leptin levels (8) . Additionally, the affected adult of this kindred also showed failure of pubertal development. The R105W mutant leptin has been shown to exhibit defective secretion in transient transfected COS cells (8) . We have extended this observation to transfected CHO cells. These results indicate that impaired intracellular trafficking of R105W leptin is the likely molecular mechanism underlying the hypoleptinemia and severe obesity described. No detailed studies of the cellular itinerary of R105W mutation have, as yet, been presented.
In both families with mutations in leptin thus far described, heterozygote family members seem not to be markedly clinically affected and have leptin levels within the range predicted on the basis of their body mass index. This suggests that the mutant leptins are unlikely to interfere with the secretion of wt leptin, and we have confirmed this in the case of the ⌬133 mutation. The mechanism whereby the single remaining allele up-regulates its expression to maintain normal leptin levels and normal body weight remains an area for future investigation.
It is possible that understanding of the precise cell biological defects associated with mutant forms of leptin may lead to therapeutic advances. Various low-molecular-weight compounds (glycerol, trimethylamine-N oxide or deuterated water), which are known to stabilize proteins in their native conformation, are effective in correcting the temperaturesensitive protein-folding defect associated with the ⌬F508 CFTR protein (21) . This is also true for mutants of the tumorsuppressor protein p53, the viral oncogene protein pp60src, and the ubiquitin-activating enzyme E1 (21) .
We therefore reasoned that such treatment of cells expressing the R105W leptin might assuage the block on secretion. However, incubation of cells, either with glycerol or at reduced temperature, did not facilitate secretion of the R105W leptin. The finding that incubation at reduced temperature did not rescue secretion of the R105W leptin rules out the possibility that the R105W leptin is a temperaturesensitive mutant. Whether this mutation also affects leptin binding has not been tested. As expected, similar treatment of cells expressing the ⌬133 leptin had no effect on secretion.
In summary, we have more precisely defined the molecular basis for defective leptin secretion in subjects with congenital leptin deficiency. These findings add to our understanding of the relationship between genotype and phenotype in this novel clinical syndrome.
